Overview

Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE

Status:
Completed

Trial end date:
2019-10-31

Target enrollment:

Participant gender:

Summary

This study is an open-label, long term safety and efficacy study to evaluate DX-2930 in preventing acute angioedema attacks in participants with Type I and Type II HAE.

Phase:

Phase 3

Details

Lead Sponsor:

Shire

Collaborator:

Dyax Corp.

Treatments:

Antibodies, Monoclonal